Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD)
Active, not recruiting · NCT07741526 · Registry updated 2026-08-03Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Safety, Tolerability and Biomarker-based Efficacy of NPI-001 (AT-001) in Subjects With MCI or Alzheimer's Disease (AD) | Cognition Disorders, Cognitive Dysfunction, brain disorder, central nervous system disorder, cognitive disorder, dementia, nervous system disorder, psychiatric disorder | Active, not recruiting | Phase 2 | 2026-08-03 | NCT07741526 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Arctic Therapeutics | 2 |
| Blueskin AS | 1 |
4 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| Landspitali University Hospital | Reykjavik | Iceland | 2 |
| Sanos Clinic Gandrup | Gandrup | Denmark | 1 |
| Sanos Clinic Herlev | Herlev | Denmark | 3 |
| Sanos Clinic Vejle | Vejle | Denmark | 1 |